nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

22.11.2022 | Letter to the Editor

Validation and utility of HepG2 xenograft model for hepatocellular carcinoma

verfasst von: Yangmeihui Song, Qiaomiao Lu, Dawei Jiang, Xiaoli Lan

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Excerpt

We thank Li’s comments and interest in our recent article [1]. After careful authentication of the HepG2 cell line used in our study, we believe the raised concerns regarding possible cell contamination and misusage can be resolved. During the study, cells were handled with extreme care in a strictly controlled environment for cellular and animal studies. In addition, we confirmed HepG2 cells by performing the short tandem repeat analysis (Fig. 1). …

Li Z. Letter to the editor regarding “PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [(68) Ga]Ga-PSMA-617.” Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-06005-2.CrossRef

Santos NP, Colaço AA, Oliveira PA. Animal models as a tool in hepatocellular carcinoma research: a review. Tumour Biol. 2017;39(3):1010428317695923. https://doi.org/10.1177/1010428317695923.CrossRef

Li H, Jiang D, Zhang L, Wu J. Inhibition of tumor growth of human hepatocellular carcinoma HepG2 cells in a nude mouse xenograft model by the total flavonoids from Arachniodes exilis. Evid Based Complement Alternat Med. 2017;2017:5310563. https://doi.org/10.1155/2017/5310563.CrossRef

Roy G, Guan S, Liu H, Zhang L. Rotundic acid induces DNA damage and cell death in hepatocellular carcinoma through AKT/mTOR and MAPK pathways. Front Oncol. 2019;9:545. https://doi.org/10.3389/fonc.2019.00545.CrossRef

Li H, Feng Z, Tsang TC, Tang T, Jia X, He X, et al. Fusion of HepG2 cells with mesenchymal stem cells increases cancer-associated and malignant properties: an in vivo metastasis model. Oncol Rep. 2014;32(2):539–47. https://doi.org/10.3892/or.2014.3264.CrossRef

Zhu H, Wang DD, Yuan T, Yan FJ, Zeng CM, Dai XY, et al. Multikinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis. Cancer Res. 2018;78(14):3995–4006. https://doi.org/10.1158/0008-5472.CAN-17-1548.CrossRef

Chen H, Wei X, Chen H, Wei H, Wang Y, Nan W, et al. The study of establishment of an in vivo tumor model by three-dimensional cells culture systems methods and evaluation of antitumor effect of biotin-conjugated pullulan acetate nanoparticles. Artif Cells Nanomed Biotechnol. 2019;47(1):123–31. https://doi.org/10.1080/21691401.2018.1544142.CrossRef

Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 2020;158(8):2250-2265.e20. https://doi.org/10.1053/j.gastro.2020.02.011.CrossRef

Wu CD, Lee JC, Wu HC, Lee CW, Lin CF, Hsu MC, et al. Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy. Nanobiomedicine (Rij). 2019;6:1849543519880762. https://doi.org/10.1177/1849543519880762.CrossRef

10.

de Oliveira FP, Da CRACB, de Lima EJ, Silva VR, de Santos LS, de Anunciação TA, et al. Essential oil from bark of Aniba parviflora (Meisn.) Mez (Lauraceae) reduces HepG2 cell proliferation and inhibits tumor development in a xenograft model. Chem Biodivers. 2021;18(3):e2000938. https://doi.org/10.1002/cbdv.202000938.CrossRef

11.

Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011;11(5):524–34. https://doi.org/10.4161/cbt.11.5.14677.CrossRef

12.

Pandit H, Li Y, Zheng Q, Guo W, Yu Y, Li S, et al. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget. 2020;11(22):2047–60. https://doi.org/10.18632/oncotarget.27454.CrossRef

13.

Labadie KP, Hamlin DK, Kenoyer A, Daniel SK, Utria AF, Ludwig AD, et al. Glypican-3-targeted 227Th α-therapy reduces tumor burden in an orthotopic xenograft murine model of hepatocellular carcinoma. J Nucl Med. 2022;63(7):1033–8. https://doi.org/10.2967/jnumed.121.262562.CrossRef

14.

Arzumanian VA, Kiseleva OI, Poverennaya EV. The curious case of the HepG2 cell line: 40 years of expertise. Int J Mol Sci. 2021;22(23):13135. https://doi.org/10.3390/ijms222313135.CrossRef

15.

Hajighasemlou S, Pakzad S, Ai J, Muhammadnejad S, Mirmoghtadaei M, Hosseinzadeh F, et al. Characterization and validation of hepatocellular carcinoma (HCC) xenograft tumor as a suitable liver cancer model for preclinical mesenchymal stem cell studies. Asian Pac J Cancer Prev. 2018;19(6):1627–31. https://doi.org/10.22034/APJCP.2018.19.6.1627.CrossRef

16.

Zhai BJ, Shao ZY, Zhao CL, Hu K, Wu F. Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice. World J Gastroenterol. 2006;12(41):6614–9. https://doi.org/10.3748/wjg.v12.i41.6614.CrossRef

17.

Chouhan S, Singh S, Athavale D, Ramteke P, Pandey V, Joseph J, et al. Glucose induced activation of canonical Wnt signaling pathway in hepatocellular carcinoma is regulated by DKK4. Sci Rep. 2016;6:27558. https://doi.org/10.1038/srep27558.CrossRef

18.

Woodfield SE, Shi Y, Patel RH, Jin J, Major A, Sarabia SF, et al. A novel cell line based orthotopic xenograft mouse model that recapitulates human hepatoblastoma. Sci Rep. 2017;7(1):17751. https://doi.org/10.1038/s41598-017-17665-8.CrossRef

19.

Zhao R, Wang TZ, Kong D, Zhang L, Meng HX, Jiang Y, et al. Hepatoma cell line HepG2.2.15 demonstrates distinct biological features compared with parental HepG2. World J Gastroenterol. 2011;17(9):1152–9. https://doi.org/10.3748/wjg.v17.i9.1152.CrossRef

Titel: Validation and utility of HepG2 xenograft model for hepatocellular carcinoma
verfasst von: Yangmeihui Song
Qiaomiao Lu
Dawei Jiang
Xiaoli Lan
Publikationsdatum: 22.11.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06043-w

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

The potential of a medium-cost long axial FOV PET system for nuclear medicine departments

Letter to the editor: Combined [68 Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy

Predicting pathological highly invasive lung cancer from preoperative [18F]FDG PET/CT with multiple machine learning models

[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial

123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation

Letter to Editor for “European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees.”